An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p = ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:LEUKEMIA & LYMPHOMA 2019-03, Vol.60 (4), p.1030-1035
Hauptverfasser: Sobas, Marta, Montesinos, Pau, Boluda, Blanca, Bernal, Teresa, Vellenga, Edo, Nomdedeu, Josep, Gonzalez-Campos, Jose, Chillon, Maria, Holowiecka, Aleksandra, Esteve, Jordi, Bergua, Juan, David Gonzalez-Sanmiguel, Jose, Gil-Cortes, Cristina, Tormo, Mar, Salamero, Olga, Manso, Felix, Fernandez, Isolda, de la Serna, Javier, Moreno, Maria-Jose, Perez-Encinas, Manuel, Krsnik, Isabel, Ribera, Josep-Maria, Escoda, Lourdes, Lowenberg, Bob, Angel Sanz, Miguel, Beltran de Heredia, J.M, Hernandez, J.M, Arias, J, Ramos, F, Roman, A, Negri, S, Rayon, C, Fernandez-Calvo, F.J, Diaz-Mediavilla, J, Gil, C, Olave, M, Amutio, E, Pedro, C, Gorosquieta, A, Viguria, M, Zudaire, M, Molero, T, Sayas, M.J, Guardia, R, Esquembre, C, Garcia, R, Alcala, A, Lopez, J.A, Rubio, V, Amigo, M.L, Linares, M, Gonzalez San Miguel, J.D, Coruna, A, Deben, G, de la Camara, R, Molines, A, Loureiro, C, Allegue, M.J, Amador, L, Marti, J.M, Madero, L, Lassaletta, A, Cabezudo, M, Garcia-Larana, J, Rojas, R, Ortega, F, Penarrubia, M.J, Puente, F, Lopez-Ibor, B, Brunet, S, Ibanez, J, Sanchez, P, Novo, A, Guinea, J.M, Montero, A, Gonzalez, M, Martin, G, Martinez, J, Verdeguer, A, Garcia, P, Conde, E, Garcia, J, Capote, F.J, Bueno, J, Bastida, P, Rubio, A, Fuster, J.L, Gonzalez, J, Perez, I, Molina, J, Mateos, M.C, Ardaiz, M.A, Rodriguez-calvillo, M, Poderos, C, Arnan, M, Duarte, R, Diaz-Morfa, M, Martin-Chacon, E, Calvo-Villas, J.M, Garcia-Belmonte, D
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p = .02) and 5-years cumulative incidence of relapse (33% versus 10%, p = .006), irrespectively of the Sanz score (low-risk 47% versus 5%, p 
ISSN:1042-8194